Finally, we also wished to confirm the efficacy of ETC complex II inhibition in glycolytic (Fig. 5f–i) and OXPHOS-dependent (Fig. 5j–n) leukemias in vivo and we also tested the combination of ETC complex II and lactate transporter inhibition in vivo in FLT3-ITD+ AML (Fig. 5j). Here, FLT3 is linked to leukemia.